<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5210088 Figure_1-A</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 1-A</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Chemical structure of Nec-1. The schematic diagram was drawn by S. Lee using ChemDraw Professional 15.0. software.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_1-B</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 1-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-B</infon>
    <passage>
      <offset>0</offset>
      <text>B, C. MTT cytotoxicity assay. (B) HT22 cell line was treated with various concentrations of Nec-1 (0 - 200 &#956;M). Aggregated A&#946;(1-42) was used as the positive control for the induction of neural cell death. All data represented the mean &#177; standard deviation of three independent experiments performed in triplicate.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_1-C</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>B, C. MTT cytotoxicity assay. (C) HT22, BV2 cell lines and primary astrocytes were pre-treated with Nec-1 (50 &#956;M) 15 minutes prior to application of 10 &#956;M of pre-aggregated A&#946;(1-42) for indicated times. Cell proliferation was then measured by MTT assay. All data represented the mean &#177; standard deviation of three independent experiments performed in triplicate.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_1-D-E</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 1-D-E</infon>
    <infon key="sourcedata_figure_dir">Figure_1-D-E</infon>
    <passage>
      <offset>0</offset>
      <text>D, E. Neural cell death levels measured by staining with the Live/Dead Viability/Cytotoxicity Assay Kit (Molecular Probes). Pre-treatment of cells with 50 &#956;M Nec-1 preceded the application of 10 &#956;M pre-aggregated A&#946;(1-42) by 15 minutes. The assay was performed 24 hours after A&#946;(1-42) application. (D) Representation of the stained cells. Scale bar = 500 &#956;m (E) Quantification of dead cells stained by EthD-1.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_1-F</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 1-F</infon>
    <infon key="sourcedata_figure_dir">Figure_1-F</infon>
    <passage>
      <offset>0</offset>
      <text>F. Internalization of A&#946;(1-42) into HT22 and BV2 cell lines in the presence or the absence of Nec-1 pre-treatment for indicated periods.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_1-G</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 1-G</infon>
    <infon key="sourcedata_figure_dir">Figure_1-G</infon>
    <passage>
      <offset>0</offset>
      <text>G. Cellular expression levels of indicated proteins in HT22, BV2 cell lines, and primary astrocyte stimulated with A&#946;(1-42) aggregates in the presence or the absence of Nec-1 pre-treatment for 24 hours.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_2-B-C-D</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 2-B-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_2-B-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>A-E. Behavioural tests of APP/PS1mice. (B-D) Y-maze and passive avoidance tests on 7-month-old APP/PS1mice after Nec-1 administration for 12 weeks. Average alternation (%) for each test group (B) and total entry number into each arm (C) on Y-maze. (D) Average latency time in seconds for each test group on passive avoidance test.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_2-E</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 2-E</infon>
    <infon key="sourcedata_figure_dir">Figure_2-E</infon>
    <passage>
      <offset>0</offset>
      <text>A-E. Behavioural tests of APP/PS1mice. (E) Survival of Wt and APP/PS1mice after injection of Nec-1 (6.25 mg/kg).</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_2-H-I</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 2-H-I</infon>
    <infon key="sourcedata_figure_dir">Figure_2-H-I</infon>
    <passage>
      <offset>0</offset>
      <text>F-I. Behavrioural tests of A&#946;(1-42) infusion mice. (H, I) Y-maze tests on A&#946;(1-42) infusion mice model injected with Nec-1. Average alternation (%) for each test group (H) and total entry number into each arm (I) on Y-maze.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_3-A</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 3-A</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Co-immunoprecipitation of RIPK3 with A&#946;(1-42) in HT22, BV2 cell lines, and primary astrocytes in response to A&#946;(1-42) aggregates. IP, immunoprecipitation; IB, immunoblot.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_3-B</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 3-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. A close-up view of the interactions between Nec-1 and surrounding residues in RIPK1. Nec-1 is shown in green. The hydrophobic residues around Nec-1 in RIPK1 kinase domain are shown in sticks. Hydrogen bonds in this and all other figures are represented by yellow dashed lines. Docking score of Nec-1 in RIPK1 was -9.550.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_3-C</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 3-C</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Surface treated view of 12-mer A&#946; fibrils (2LMO, VDW radius = 0.55 &#197;) having hydrophobic pockets plausible for Nec-1 binding.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_3-D</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 3-D</infon>
    <infon key="sourcedata_figure_dir">Figure_3-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Docked structure of 12-mer A&#946; fibrils (2LMO) with 4 molecules of Nec-1. Docking scores for four top-ranked Glide docking poses of Nec-1 in A&#946; plaques; -8.338, -4.755, -8.493, and -6.754 in clockwise order starting from the top-left corner.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_3-E</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 3-E</infon>
    <infon key="sourcedata_figure_dir">Figure_3-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. Surface plasmon resonance sensorgrams of Nec-1 targeting A&#946;(1-42) aggregates (left), and the corresponding dissociation fitting curve from the saturated region (right) under various concentrations of Nec-1.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_4-A-G</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 4-A-G</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A-G</infon>
    <passage>
      <offset>0</offset>
      <text>4-month-old APP/PS1 (n = 13, male) and age-matched wild-type (Wt, n = 14, male) mice were intravenously injected with Nec-1 (6.25 mg/kg) or vehicle (2.5% DMSO in PBS) for 12 weeks. After the completion of behavioural tests, the brains of each group of mice were subjected to analysis. A. ThS-stained insoluble A&#946;plaques in whole brain and the hippocampal region of each group. Scale bars = 1 mM (upper), 200 &#956;M (lower). B-G. Statistics of ThS-positive A&#946;plaques in the brains of APP/PS1mice. Total numbers and areas of ThS-positive A&#946;plaques in the whole brains (B and C), cortex (D and E) and hippocampus (F and G).</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_5-A</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 5-A</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Immunohistochemical analysis of cortical and hippocampal regions of the brains in wild-type (Wt) and APP/PS1mice after administration of Nec-1 (6.25 mg/kg) or vehicle (2.5% DMSO in PBS). Diffuse plaques in the brain sections were stained by anti-A&#946; antibody (6E10 clone, green colour) and anti-GFAP antibody (red colour). Hoechst 33342 (blue colour) was applied for nuclear counterstaining. Scale bars = 200 &#956;M.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_5-B-C</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 5-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_5-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>B-D. Dot blot analysis of total A&#946; (anti-A&#946;: 6E10 clone, also recognizes APP) and protein oligomer (anti-amyloidogenic protein oligomer A11) in the cortical (B) and hippocampal (C) region of indicated groups. (D) Quantification analysis of total A&#946; and protein oligomer in the cortical and hippocampal region of indicated groups. Relative intensity of each band was determined by densitometry of dot blots (B and C) using ImageJ software and normalized to vehicle-administered APP/PS1 mouse group.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_5-D</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 5-D</infon>
    <infon key="sourcedata_figure_dir">Figure_5-D</infon>
    <passage>
      <offset>0</offset>
      <text>B-D. Dot blot analysis of total A&#946; (anti-A&#946;: 6E10 clone, also recognizes APP) and protein oligomer (anti-amyloidogenic protein oligomer A11) in the cortical (B) and hippocampal (C) region of indicated groups. (D) Quantification analysis of total A&#946; and protein oligomer in the cortical and hippocampal region of indicated groups. Relative intensity of each band was determined by densitometry of dot blots (B and C) using ImageJ software and normalized to vehicle-administered APP/PS1 mouse group.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_5-E</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 5-E</infon>
    <infon key="sourcedata_figure_dir">Figure_5-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. Sandwich ELISA of A&#946;-soluble and -insoluble fractions from cortical and hippocampal lysates of APP/PS1mice.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_5-F</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 5-F</infon>
    <infon key="sourcedata_figure_dir">Figure_5-F</infon>
    <passage>
      <offset>0</offset>
      <text>F. Western blot analyses of cortical and hippocampal lysates from APP/PS1mice for APP and sAPP expressions.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_5-G</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 5-G</infon>
    <infon key="sourcedata_figure_dir">Figure_5-G</infon>
    <passage>
      <offset>0</offset>
      <text>G. ThT assays for the inhibition of A&#946; aggregation. Fluorescence intensity was normalized to A&#946; aggregates (100%, day 5).</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_5-H</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 5-H</infon>
    <infon key="sourcedata_figure_dir">Figure_5-H</infon>
    <passage>
      <offset>0</offset>
      <text>H. SDS-PAGE analysis of PICUP cross-linked A&#946; aggregates visualized by silver staining.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_6-A</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 6-A</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Western blot analysis of phosphorylation levels of tau and expression levels of indicated proteins in the cortical and hippocampal regions of the brain in APP/PS1mice after administration of Nec-1 (6.25 mg/kg) or vehicle (2.5% DMSO in PBS). The membranes analysed in (A) are identical to those in Fig 5F.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_6-B</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 6-B</infon>
    <infon key="sourcedata_figure_dir">Figure_6-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Immunohistochemical analysis of cortical and hippocampal regions of the brains in wild-type (Wt) and APP/PS1 mice after administration of Nec-1 (6.25 mg/kg) or vehicle (2.5% DMSO in PBS) for phosphorylated tau expression levels. Anti-tau (phospho Ser199) antibody (red colour) was applied for staining tau phosphorylation on Serine-199 and Hoechst 33342 (blue colour) for nuclear counterstaining in the brain sections. Scale bars = 200 &#956;M.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_6-C-1</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 6-C-1</infon>
    <infon key="sourcedata_figure_dir">Figure_6-C-1</infon>
    <passage>
      <offset>0</offset>
      <text>C. Western blot analyses of phosphorylated RIPK3 expressions in cortex and hippocampus of APP/PS1 mice injected with Nec-1 (upper). The membranes analysed in (C) are identical to those in Fig 1G and 5F.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_6-C-2</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 6-C-2</infon>
    <infon key="sourcedata_figure_dir">Figure_6-C-2</infon>
    <passage>
      <offset>0</offset>
      <text>C. Western blot analyses of phosphorylated RIPK3 expressions in primary cultured astrocytes treated with Nec-1 (lower). The membranes analysed in (C) are identical to those in Fig 1G and 5F.</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_6-D-E</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 6-D-E</infon>
    <infon key="sourcedata_figure_dir">Figure_6-D-E</infon>
    <passage>
      <offset>0</offset>
      <text>D, E. ThT assays for the inhibition of tau aggregation (D) and for disaggregation of tau (E). Fluorescence intensity was normalized to tau aggregates (100%, day 5).</text>
    </passage>
  </document>
  <document>
    <id>5210088 Figure_6-F</id>
    <infon key="sourcedata_document">2465</infon>
    <infon key="doi">10.15252/emmm.201606566</infon>
    <infon key="pmc_id">5210088</infon>
    <infon key="figure">Figure 6-F</infon>
    <infon key="sourcedata_figure_dir">Figure_6-F</infon>
    <passage>
      <offset>0</offset>
      <text>F. Surface plasmon resonance sensorgrams of Nec-1 targeting tau (left), and the corresponding dissociation fitting curve from the saturated region (right) under various concentrations of Nec-1.</text>
    </passage>
  </document>
</collection>
